The ADA 2026 Standards of Care now recommend GLP-1 receptor agonists with demonstrated cardiovascular benefit for patients with type 2 diabetes and established ASCVD, multiple cardiovascular risk factors, or chronic kidney disease, and note that combination with SGLT2 inhibitors may provide additive benefit
Response may vary across age groups, though evidence for consistent age-related differences in onset of action is limited
Rizzo M, Nikolic D, Patti AM, Mannina C, Montalto G, McAdams BS, Rizvi AA, Cosentino F
The reduced appetite makes every calorie count more, and the autoimmune condition places specific demands on dietary composition
Sasha clinic brings the silk peel for glowing skin
Some people also use it topically for skin, separately from the injectable